Eli Lilly to Acquire Merida Biosciences
Analysis based on 26 articles · First reported Aug 31, 2026 · Last updated Aug 31, 2026
The acquisition strengthens Eli Lilly's immunology pipeline with a novel precision antibody-degradation platform, potentially expanding its market in autoimmune and allergic disease treatments. The deal is expected to close in Q4 2026, with Lilly's stock slightly down on the news, reflecting the upfront cash outlay and early-stage nature of the assets.
Eli Lilly and Company announced a definitive agreement to acquire Merida Biosciences, a privately held biotechnology company developing precision therapeutics for autoimmune and allergic diseases, for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The acquisition adds Merida's antibody-engineering platform, designed to selectively degrade pathogenic autoantibodies while preserving normal immune function, and its lead Phase 1 candidate MER511 for Graves' disease and thyroid eye disease. Merida's pipeline also includes MER769, a preclinical program for IgE-mediated allergic diseases, and earlier-stage programs for kidney and other immune-mediated conditions. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals. Lilly's shares were down about 1.7% on the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard